

**ABOUT THE TEST** FoundationOne®Liquid is a next generation sequencing (NGS) assay that identifies clinically relevant genomic alterations in circulating tumor DNA.

**PATIENT**

DISEASE Lung adenocarcinoma  
NAME Not Given  
DATE OF BIRTH Not Given  
SEX Not Given  
MEDICAL RECORD # Not Given

**PHYSICIAN**

ORDERING PHYSICIAN Not Given  
MEDICAL FACILITY Not Given  
ADDITIONAL RECIPIENT Not Given  
MEDICAL FACILITY ID Not Given  
PATHOLOGIST Not Given

**SPECIMEN**

SPECIMEN ID Not Given  
SPECIMEN TYPE Blood  
DATE OF COLLECTION Not Given  
SPECIMEN RECEIVED Not Given

**Biomarker Findings**  
MSI Status Undetermined

**Genomic Findings**  
*For a complete list of the genes assayed, please refer to the Appendix.*  
**EGFR** exon 19 deletion (L747\_A750>P)  
**TP53** C242G

7 Therapies with Clinical Benefit  
0 Therapies with Lack of Response

10 Clinical Trials

**BIOMARKER FINDINGS**

**ACTIONABILITY**

**MSI Status Undetermined**

**GENOMIC FINDINGS**

**MAF %**

**EGFR -** exon 19 deletion (L747\_A750>P) 0.20%

**THERAPIES WITH CLINICAL BENEFIT  
(IN PATIENT'S TUMOR TYPE)**

**THERAPIES WITH CLINICAL BENEFIT  
(IN OTHER TUMOR TYPE)**

10 Trials see p. 8

**GENOMIC FINDINGS WITH NO REPORTABLE THERAPEUTIC OR CLINICAL TRIALS OPTIONS**

*For more information regarding biological and clinical significance, including prognostic, diagnostic, germline, and potential chemosensitivity implications, see the Genomic Findings section.*


**TP53 - C242G**

p. 3

**NOTE:** Genomic alterations detected may be associated with activity of certain FDA-approved drugs; however, the agents listed in this report may have varied clinical evidence in the patient's tumor type. Neither the therapeutic agents nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type. In the appropriate clinical context, germline testing of APC, BRCA1, BRCA2, CDH1, NF1, PALB2, RB1, RET, STK11, and TP53 is recommended.

Mutant Allele Frequency is not applicable for copy number amplifications or rearrangements.

CRF# XXXXXXXX



HISTORIC PATIENT FINDINGS	TEST 1	TEST 2 MAF%	TEST 3 MAF%	CHANGE FROM PREV.
<b>Tumor Mutational Burden</b>	Cannot Be Determined	Not Tested	Not Tested	—
<b>Microsatellite status</b>	Cannot Be Determined	n/a	n/a	—
<b>EGFR</b> ● exon 19 deletion (L747_A750>P)	detected	23.00%	0.20%	-22.8%
<b>TP53</b> ● C242G	detected	12.50%	0.10%	-12.40%

**NOTE** This comparison table refers only to genes and biomarkers assayed by prior FoundationOne®Liquid or FoundationOne® tests. Up to five previous tests may be shown.

For some genes in FoundationOne Liquid only select exons are assayed. Therefore, an alteration found by a previous test may not have been confirmed despite overlapping gene lists. Please refer to the Appendix for the complete list of genes and exons assayed. The gene and biomarker list will be updated periodically to reflect new knowledge about cancer biology.

As new scientific information becomes available, alterations that had previously been listed as Variants of Unknown Significance (VUS) may become reportable.